BioCentury | Jun 28, 2012
Targets & Mechanisms

Endostatin for fibrosis

...transferred rights to the peptide back to the original owner- Boston Children's Hospital -and to Alchemgen Therapeutics Inc....
...26); doi:10.1038/scibx.2012.671Published online June 28, 2012 Companies and Institutions Mentioned Actelion Ltd. (SIX:ATLN), Allschwil, Switzerland Alchemgen Therapeutics Inc....
BioCentury | Feb 9, 2004
Company News

Alchemgen Therapeutics Inc., EntreMed, The Children's Medical Center Corp. deal

...ENMD transferred to Alchemgen and the Children's Medical Center all rights to its endostatin and angiostatin...
...and the Children's Medical Center all rights to its endostatin and angiostatin therapeutic protein programs. Alchemgen...
...2-methoxyestradiol ( 2ME2 ), which is in Phase II development to treat multiple myeloma (MM). Alchemgen Therapeutics Inc....
BioCentury | Feb 4, 2004
Company News

EntreMed transfers its angiostatin, endostatin rights

...ENMD transferred to Alchemgen (Houston, Texas) and to Children's Medical Center Corp. (Boston, Mass.) all rights...
...Medical Center Corp. (Boston, Mass.) all rights to its endostatin and angiostatin therapeutic protein programs. Alchemgen...
Items per page:
1 - 3 of 3
BioCentury | Jun 28, 2012
Targets & Mechanisms

Endostatin for fibrosis

...transferred rights to the peptide back to the original owner- Boston Children's Hospital -and to Alchemgen Therapeutics Inc....
...26); doi:10.1038/scibx.2012.671Published online June 28, 2012 Companies and Institutions Mentioned Actelion Ltd. (SIX:ATLN), Allschwil, Switzerland Alchemgen Therapeutics Inc....
BioCentury | Feb 9, 2004
Company News

Alchemgen Therapeutics Inc., EntreMed, The Children's Medical Center Corp. deal

...ENMD transferred to Alchemgen and the Children's Medical Center all rights to its endostatin and angiostatin...
...and the Children's Medical Center all rights to its endostatin and angiostatin therapeutic protein programs. Alchemgen...
...2-methoxyestradiol ( 2ME2 ), which is in Phase II development to treat multiple myeloma (MM). Alchemgen Therapeutics Inc....
BioCentury | Feb 4, 2004
Company News

EntreMed transfers its angiostatin, endostatin rights

...ENMD transferred to Alchemgen (Houston, Texas) and to Children's Medical Center Corp. (Boston, Mass.) all rights...
...Medical Center Corp. (Boston, Mass.) all rights to its endostatin and angiostatin therapeutic protein programs. Alchemgen...
Items per page:
1 - 3 of 3